Long-term outcomes of hematopoietic stem cell transplantation in patients with multiple sclerosis

Takeaway

  • Autologous hematopoietic stem cell transplantation (aHSCT) prevents worsening disability in most patients and induces lasting improvement in disability in patients with relapsing remitting multiple sclerosis (RRMS).

Why this matters

  • Intense immunosuppression followed by aHSCT (aims to induce cell self-tolerance via extensive renewal of the immune system) has been explored as a treatment strategy for aggressive MS; however, outcome data has generally been limited to short-term follow-up.

  • The positive long-term clinical outcomes of aHSCT in MS may significantly impact future treatment and management strategies for this condition, improving long-term quality of life and emotional outcomes for patients.